MARK VAN BLANKENSTEIN

8.0k citations

115 papers · 6.5k · 1 hit paper · h-index 41

Impact in

Gastroenterology top 0.5%
- Gastroesophageal reflux and treatments
Surgery top 0.5%
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Helicobacter pylori-related gastroenterology studies

Papers in

Surgery 86
- Esophageal Cancer Research and Treatment 31
- Esophageal and GI Pathology 19
- Pediatric Hepatobiliary Diseases and Treatments 12
- Pancreatitis Pathology and Treatment 7
- Eosinophilic Esophagitis 7
Pulmonary and Respiratory Medicine 38
- Gallbladder and Bile Duct Disorders 15
- Gastric Cancer Management and Outcomes 12

Co-authors: Jan Dees (23 shared papers)Wim C.J. Hop (13 shared papers)Hugo W. Tilanus (12 shared papers)S Shivananda (2 shared papers)A B Price (1 shared paper)J E Lennard‐Jones (1 shared paper)Nicola T. Fear (1 shared paper)Richard F. Logan (1 shared paper)
Journals: Endoscopy (14 papers)Gut (13 papers)Gastroenterology (8 papers)Scandinavian Journal of Gastroenterology (7 papers)European Journal of Gastroenterology & Hepatology (7 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

MARK VAN BLANKENSTEIN

111 papers receiving 6.1k citations

MARK VAN BLANKENSTEIN's Hit Papers

align trajectories log scale

Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). 1996 · 825 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

1996 Gut

Peers

Countries citing papers authored by MARK VAN BLANKENSTEIN

Since Specialization

Citations

This map shows the geographic impact of MARK VAN BLANKENSTEIN's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MARK VAN BLANKENSTEIN with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MARK VAN BLANKENSTEIN more than expected).

Fields of papers citing papers by MARK VAN BLANKENSTEIN

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MARK VAN BLANKENSTEIN. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MARK VAN BLANKENSTEIN. The network helps show where MARK VAN BLANKENSTEIN may publish in the future.

Co-authors

The 25 scholars most cited alongside MARK VAN BLANKENSTEIN, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with MARK VAN BLANKENSTEIN Line = papers co-authored together MARK VAN BLANKENSTEIN links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut ·S Shivananda, J E Lennard‐Jones, Richard F. Logan, Nicola T. Fear, A B Price, Lidia Teresita Ramos Carpenter, MARK VAN BLANKENSTEIN Hit paper breakdown →	1996	825
2	Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver Gastroenterology ·Felix E. de Jongh, Harry L.A. Janssen, Robert Auke de Man, Wim C.J. Hop, Solko Walle Schalm, MARK VAN BLANKENSTEIN	1992	363
3	Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer Gastroenterology ·Onno T. Terpstra, MARK VAN BLANKENSTEIN, Jan Dees, Guus A.M. Eilers	1987	285
4	Electrogastrographic study of gastric myoelectrical activity in patients with unexplained nausea and vomiting. Gut ·Han Geldof, E. J. van der Schee, MARK VAN BLANKENSTEIN, Jan L. Grashuis	1986	271
5	Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut ·Anna van der Burgh, Jan Dees, Wim C.J. Hop, MARK VAN BLANKENSTEIN	1996	269
6	Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study Gut ·Pieter Jan F. de Jonge, MARK VAN BLANKENSTEIN, Caspar W.N. Looman, Mariel K. Casparie, Gerrit A. Meijer +1 other	2010	224
7	A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: A prospective, randomized study Gastrointestinal Endoscopy ·Peter Derk Siersema, Wim C.J. Hop, MARK VAN BLANKENSTEIN, Antonie J.P. van Tilburg, Dirk–Jan Bac, Marjolein Y.V. Homs, Ernst Johan Kuipers	2001	193
8	Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus Cancer ·Marian B. E. Menke‐Pluymers, Wim C.J. Hop, Jan Dees, MARK VAN BLANKENSTEIN, Hugh W. Tilanus	1993	182
9	Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut ·Alexander H. Van Der Veen, Jan Dees, Jan D. Blankensteijn, MARK VAN BLANKENSTEIN	1989	176
10	Coated self-expanding metal stents versus latex prostheses for esophagogastric cancer with special reference to prior radiation and chemotherapy: a controlled, prospective study Gastrointestinal Endoscopy ·Peter Derk Siersema, Wim C.J. Hop, Jan Dees, Hugo W. Tilanus, MARK VAN BLANKENSTEIN	1998	170
11	Benign anastomotic strictures after transhiatal esophagectomy and cervical esophagogastrostomy: Risk factors and management Journal of Thoracic and Cardiovascular Surgery ·Pieter Honkoop, Peter D. Siersema, H.W. Tilanus, Laurents P. S. Stassen, W. C. J. Hop, MARK VAN BLANKENSTEIN	1996	151
12	Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis The Journal of Pathology ·Kausilia Krishnawatie Krishnadath, Hugo W. Tilanus, MARK VAN BLANKENSTEIN, Willem C. J. Hop, Elisa D. Kremers, Winand N.M. Dinjens, Fred T. Bosman	1997	149
13	Malignant biliary obstruction: percutaneous use of self-expandable stents. Radiology ·Johan S. Laméris, Jaap Stoker, H. G. T. Nijs, Harmien M. Zonderland, Onno T Terpstra, MARK VAN BLANKENSTEIN, Hans Schutte	1991	127
14	Guidelines for the Application of Surgery and Endoprostheses in the Palliation of Obstructive Jaundice in Advanced Cancer of the Pancreas Annals of Surgery ·René van den Bosch, George P. van der Schelling, Jean H. G. Klinkenbijl, Paul G.H. Mulder, MARK VAN BLANKENSTEIN, Johannes J. Jeekel	1994	117
15	Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut ·Marian B. E. Menke‐Pluymers, N W Schoute, Arjen Mulder, Wim C.J. Hop, MARK VAN BLANKENSTEIN, Hugo W. Tilanus	1992	113
16	Achalasia complicated by oesophageal squamous cell carcinoma: a prospective study in 195 patients. Gut ·Maarten A.C. Meijssen, Hugo W. Tilanus, MARK VAN BLANKENSTEIN, Wim C.J. Hop, GIOK L. ONG	1992	108
17	Endoscopic Papillotomy for Common Bile Duct Stones: Factors Influencing the Complication Rate Endoscopy ·J. Boender, G. A. J. J. Nix, M. A. J. de Ridder, MARK VAN BLANKENSTEIN, Hans Schutte, Jan Dees, J. H. P. Wilson	1994	108
18	Barrett's oesophagus: epidemiology, cancer risk and implications for management Gut ·Pieter Jan F. de Jonge, MARK VAN BLANKENSTEIN, William M. Grady, Ernst Johan Kuipers	2013	98
19	Causes and Treatment of Recurrent Dysphagia after Self-Expanding Metal Stent Placement for Palliation of Esophageal Carcinoma Endoscopy ·Marjolein Y.V. Homs, Ewout Willem Steyerberg, Ernst Johan Kuipers, Ate van der Gaast, Jelle Haringsma, MARK VAN BLANKENSTEIN, PD Siersema	2004	97
20	Age and Sex Distribution of the Prevalence of Barrett's Esophagus Found in a Primary Referral Endoscopy Center The American Journal of Gastroenterology ·MARK VAN BLANKENSTEIN, Caspar WN Looman, B J Johnston, CHRISTINE P. J. CAYGILL	2005	91

About MARK VAN BLANKENSTEIN

MARK VAN BLANKENSTEIN is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Gastroenterology, Oncology and Epidemiology, having authored 115 papers that have together received 6.5k indexed citations. Recurring topics across this work include Esophageal Cancer Research and Treatment (31 papers), Esophageal and GI Pathology (19 papers), Gallbladder and Bile Duct Disorders (15 papers), Pancreatic and Hepatic Oncology Research (14 papers), Gastric Cancer Management and Outcomes (12 papers), Pediatric Hepatobiliary Diseases and Treatments (12 papers), Pancreatitis Pathology and Treatment (7 papers) and Eosinophilic Esophagitis (7 papers). The work is most often cited by research in Gastroenterology (796 citations), Surgery (3.8k citations), Pulmonary and Respiratory Medicine (2.1k citations), Hepatology (326 citations) and Oncology (742 citations). MARK VAN BLANKENSTEIN has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Jan Dees, Wim C.J. Hop, Hugo W. Tilanus, S Shivananda, A B Price, J E Lennard‐Jones, Nicola T. Fear, Richard F. Logan, Ernst Johan Kuipers and Peter Derk Siersema. Their work appears in journals such as Endoscopy, Gut, Gastroenterology, Scandinavian Journal of Gastroenterology and European Journal of Gastroenterology & Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

MARK VAN BLANKENSTEIN

Impact in

Papers in i

In The Last Decade

MARK VAN BLANKENSTEIN

MARK VAN BLANKENSTEIN's Hit Papers

Peers

Countries citing papers authored by MARK VAN BLANKENSTEIN

Fields of papers citing papers by MARK VAN BLANKENSTEIN

All Works

About MARK VAN BLANKENSTEIN

Explore authors with similar magnitude of impact

Papers in